#1 Clinical Trials Search in Europe

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

3 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a new treatment for endometrial cancer, a type of cancer that begins in the lining of the uterus. The treatment being tested is called MK-2870, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific cells in the body, such as cancer cells. In this study, MK-2870 will be compared to other treatments chosen by doctors, which may include various medications that patients have previously received, such as chemotherapy and immunotherapy.

The purpose of the study is to compare the effectiveness and safety of MK-2870 with other treatments. Participants in the study will be randomly assigned to receive either MK-2870 or a treatment chosen by their doctor. The study will monitor how long participants live without their cancer getting worse and their overall survival. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will also look at how well the cancer responds to the treatment and any side effects that may occur.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of their cancer. These tests may include imaging scans to see how the cancer is responding to the treatment. The study aims to provide valuable information about the potential benefits and risks of MK-2870 for people with endometrial cancer who have already received other treatments. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

1 joining the study

Upon joining the study, the participant will be informed about the trial’s purpose, which is to compare the effectiveness and safety of MK-2870 with other treatments chosen by the physician for individuals with endometrial cancer who have previously received platinum-based chemotherapy and immunotherapy.

2 initial assessment

An initial assessment will be conducted to confirm the diagnosis of endometrial carcinoma or carcinosarcoma. This includes ensuring the disease is visible on imaging tests, either measurable or non-measurable, as per specific criteria.

3 treatment allocation

Participants will be randomly assigned to receive either MK-2870 or a treatment chosen by the physician. MK-2870 is administered as a powder for solution for injection through an intravenous infusion.

4 treatment administration

The treatment will be administered according to the assigned group. If receiving MK-2870, the participant will undergo regular intravenous infusions. The frequency and duration of these infusions will be determined by the study protocol.

5 monitoring and evaluation

Throughout the trial, participants will be monitored for progression-free survival and overall survival. This involves regular assessments using imaging tests to evaluate the response to treatment.

6 adverse events monitoring

Participants will be observed for any adverse events or side effects. The number of participants experiencing adverse events and those who discontinue the study due to these events will be recorded.

7 quality of life assessment

Changes in the participant’s global health status and quality of life will be assessed using a standardized questionnaire. This will help evaluate the impact of the treatment on daily living.

8 completion of the study

The study is expected to conclude by January 10, 2028. Participants will receive a final evaluation to assess the overall outcomes of the treatment.

Who Can Join the Study?

  • The patient must have a confirmed diagnosis of endometrial carcinoma or carcinosarcoma. This means that a doctor has determined that the patient has one of these types of cancer.
  • The patient must have a disease that can be seen on medical imaging tests. This disease can be either measurable or non-measurable according to specific guidelines used by doctors.
  • The patient must have previously received platinum-based chemotherapy. This is a type of cancer treatment that uses drugs containing the metal platinum.
  • The patient must have also received therapy targeting programmed cell death 1 protein (PD-1) or programmed cell death ligand 1 (PD-L1). These are treatments that help the immune system fight cancer.
  • The study is open to female patients only.

Who Cannot Join the Study?

  • Patients who have a different type of cancer than endometrial cancer cannot participate. Endometrial cancer is a type of cancer that starts in the lining of the uterus.
  • Only female patients are eligible for this study. Male patients cannot participate.
  • Patients who are part of a vulnerable population are not eligible. A vulnerable population includes groups of people who may have a higher risk of harm or exploitation, such as children, pregnant women, or those with certain disabilities.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Medizinische Universitaet Innsbruck Innsbruck Austria
Oncopole Claudius Regaud Toulouse France
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Kuopio University Hospital Kuopio Finland
IRCCS Humanitas Research Hospital Rozzano Italy
Medical University Of Vienna Vienna Austria
Katholieke Universiteit te Leuven Leuven Belgium
Hospital Universitario De Navarra Pamplona Spain

Other Sites

Site Name City Country Status
Diagnostic & Therapeutic Center Of Athens Hygeia Single Member S.A. Athens Greece
Centro Di Riferimento Oncologico Di Aviano Aviano Italy
Istituto Europeo Di Oncologia S.r.l. Milan Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale Naples Italy
Az Maria Middelares Gent Gent Belgium
Fakultni Nemocnice Bulovka Prague Czechia
Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o. Siedlce Poland
Karolinska University Hospital Solna Sweden
Turku University Hospital Turku Finland
Ulyjxiffrczvukvljvkiy Nduzqqpzmw Hu Tromsø Norway
Itexvcko Rqxzfzjp Dk Cejgff Dn Mgebrqnwnww Montpellier France
Csxuxx Lhrd Bbxail Lyon France
Lkgaa Unbmnhgcdqzv Mmjifkp Cjbzmow (hvart Leiden The Netherlands
Uqxphzopxngy Zofejspncp Gevb Gent Belgium
Hxaljgly Uazqfwgeaezyc 1d Dj Odrrmgu Madrid Spain
Cvnr Utqsaiitaj Hafvahpw Cork Ireland
Iggtxdpj Ckqqmy Dmgyexbpfocddtibf L'hospitalet De Llobregat Spain
Igdncmsg Tzsffh Bnbg Gpbqqkrv Prkio Ie Bari Italy
Fgakgxhlo Iveyfamgg Vxbsqcqadg Dm Oyxadyqyk Valencia Spain
Wmjrjbzuynqif Chersth Oadptkhhx Iyq Miyzp Sjfpywzvlfvnhttmsi Poznan Poland
Agmbmvi Olrdknikkrp Ovywfo Mcrfapzwip De Trfgoi Turin Italy
Bqkpoicmtnkr Cvlrilf Oxmacfdce Idv Mgbou Skbrjhuqntpaclscst W Bcghmoyuuvb Bialystok Poland
Gizkkfe Hwctwpiq Oh Phzirc Aborg Avsajnx Patras Greece
Hdyktc Hpmroizu Herlev Denmark
Uokjvendbjfwmhkaswuwe Tniffdhtt Azl Tuebingen Germany
Rmdskk Srkjf Shmgpx Ufthrtvuhvkbrdxljxi Lund Sweden
Cxsitmd Uanagcfpqmxnuzcxpoyq Byfgnc Kkx Berlin Germany
Smovoeiprjdy Hsimgmxux Ggca Heilbronn Germany
Fvskwqfh Nuhytawgt Blta Brno Czechia
Brpxshuk Uepiazmyrl Hpokymxr Cmwmgq Besançon France
Hmfsjwhz Ucnntivefm Cgywkef Hiqkuqou Helsinki Finland
Ugwxazlkrdnkwtkeoosoj Mperpwui Gqym Mannheim Germany
Fdsyduhh Nerebspwh Ksitfkrvm Vkryteqjr Prague Czechia
Nluslydnd Alys Njmu Jcisy aqkb Novy Jicin Czechia
Highirq Ptacj Dew Cicxb Dskooljlnmnkw Plerin France
Kkvxpige dqe Utsehnlgenbm Muuixcrp Apv Munich Germany
Acpzlqw Upe Izowm Ds Rtdoiu Eautiv Reggio Emilia Italy
Ryqkpbdebqejqp Copenhagen Denmark
Awgqtqt Uusdb Snxhzaemj Lsabuw Dn Bsfyqfu Bologna Italy
Amnhlib Hacrfkns Athens Greece
Upycogdysw Dvpmc Sujft Dq Bacovce Brescia Italy
Fplhuhsee Pbqd Ls Ipczeyzbmwsah Buehidjgw Dsl Hmctrenl Uqgngvhvsxxul Le Pli Madrid Spain
Sgkrfja Dx Rmhqvmajo Oqdzlfdjdjc Ceqyhjni 3u Chambray Les Tours France
Fmgnqetmdk Idqsaxvsuz Iwvbdekf Nftrntjtuus Bgwul Milan Italy
Hnbxvxsa Vabc dtwaxwpb Barcelona Spain
Cjduxp Opuzl Lfwkyal Lille France
Chkpvb Dh Lnnkg Coialv Ld Cxiknm Emlzoc Meoufvi Rennes France
Myceuwgmtrbf Hgmuhgta Athens Greece
Hibspsdge Mfgypyyw Scbxde Milan Italy
Tyqnayz Ulotokyqmj Huzhlrez Tampere Finland
Ndlgxqhe Iphhzdcy Onzfodlcw Ikc Mgutl Slfsfwfhhttrahgpnpdyxdvwyxfr Iulkimqv Byhvheds Warsaw Poland
Sxauuewal Rqwckiu Uqfzvoadho Mcygvva Clbwuh Nijmegen The Netherlands
Addnsp Umjpoyvvzb Hxffaxbw Aarhus Denmark
Viluhvmci Fwedzkbv Nnjovqdid V Pdwju Prague Czechia
Gihjwu hvfgcifaiuo Ddzxnofmkgn Cviab Srfov Saehh Paris France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
19.12.2023
Belgium Belgium
Not recruiting
19.12.2023
Czechia Czechia
Not recruiting
19.12.2023
Denmark Denmark
Not recruiting
19.12.2023
Finland Finland
Not recruiting
19.12.2023
France France
Not recruiting
19.12.2023
Germany Germany
Not recruiting
19.12.2023
Greece Greece
Not recruiting
19.12.2023
Ireland Ireland
Not recruiting
19.12.2023
Italy Italy
Not recruiting
19.12.2023
Norway Norway
Not recruiting
19.12.2023
Poland Poland
Not recruiting
19.12.2023
Spain Spain
Not recruiting
19.12.2023
Sweden Sweden
Not recruiting
19.12.2023
The Netherlands The Netherlands
Not recruiting
19.12.2023

Trial locations

Investigated Drugs:

MK-2870 is an investigational medication being studied for its effectiveness and safety in treating endometrial cancer. This medication is being tested as a monotherapy, meaning it is used alone without combining it with other treatments. The trial aims to determine how well MK-2870 works in prolonging the time patients live without their cancer getting worse and in improving overall survival rates. This study is particularly focused on patients who have already received platinum-based chemotherapy and immunotherapy.

Treatment of Physician’s Choice (TPC) refers to a range of standard treatments that a doctor may choose based on the patient’s specific condition and medical history. In this trial, TPC serves as a comparison to MK-2870 to evaluate which option provides better outcomes for patients with endometrial cancer. The specific treatments included in TPC can vary, as they are tailored to each patient’s needs and the physician’s clinical judgment.

Endometrial cancer – This is a type of cancer that begins in the lining of the uterus, known as the endometrium. It is most commonly diagnosed in women who have gone through menopause. The disease often presents with symptoms such as abnormal vaginal bleeding or discharge. As it progresses, the cancer can invade the muscular layer of the uterus and may spread to other parts of the body. The progression of endometrial cancer can vary, with some cases remaining localized while others may metastasize. Early detection is crucial for managing the disease effectively.

Trial ID:
2023-504816-14-00
Protocol code:
MK-2870-005
NCT ID:
NCT06132958
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    France Ireland Italy Romania Spain

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated Drugs:
    Belgium Czechia Denmark Finland France Germany +4